Literature DB >> 30143443

Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.

Amaya Hilario1, Aurelio Hernandez-Lain2, Juan Manuel Sepulveda3, Alfonso Lagares4, Angel Perez-Nuñez4, Ana Ramos5.   

Abstract

BACKGROUND AND
PURPOSE: Our objectives were: (1) compare dynamic susceptibility-weighted (DSC) and dynamic contrast-enhanced (DCE) permeability parameters, (2) evaluate diagnostic accuracy of DSC and DCE discriminating high- and low-grade tumors, (3) analyze relationship of permeability parameters with overall (OS) and progression-free survival (PFS) and (4) assess differences in high-grade tumors classified according to molecular biomarkers.
MATERIALS AND METHODS: 49 patients with histologically proved diffuse gliomas underwent DSC and DCE imaging. Parametric maps of cerebral blood volume (CBV), CBV-leakage corrected, volume transfer coefficient (Ktrans), fractional volume of the extravascular extracellular space (EES) (Ve), fractional blood plasma volume (Vp) and rate constant between EES and blood plasma (Kep) were calculated. High-grade gliomas were also classified according to isocitrate dehydrogenase (IDH), alpha-thalassemia/mental retardation syndrome X-linked (ATRX) and O6-methylguanine-dna-methyltransferase promoter methylation (MGMT) status.
RESULTS: There is correlation between parameters leakage, Ktrans and Vp. ROC curve analysis showed significance in both Ktrans and Ve for glioma grading. Threshold value of 0.075 for Ve generated the best combination of sensitivity (80%) and specificity (75%) in tumor gradation. Leakage was the only permeability parameter related to OS (P=0.006) and PFS (0.012); with prolonged survival for leakage values lower than 1.2. IDH-mutated high-grade tumors showed lower leakage and Ktrans values. High-grade tumors with loss of ATRX presented lower leakage and Vp values.
CONCLUSIONS: Both DSC and DCE permeability parameters serve as non-invasive method for glioma grading. Leakage was the unique permeability parameter related to survival and the best discriminating high-grade gliomas classified according to IDH and ATRX status.
Copyright © 2018 Sociedad Española de Neurocirugía. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Brain; Cerebro; Glioma; Gliomas; Neoplasias; Neoplasms; Perfusion; Perfusión; Permeabilidad; Permeability

Mesh:

Substances:

Year:  2018        PMID: 30143443     DOI: 10.1016/j.neucir.2018.06.004

Source DB:  PubMed          Journal:  Neurocirugia (Astur : Engl Ed)        ISSN: 2529-8496


  5 in total

Review 1.  A systematic review and meta-analysis on the differentiation of glioma grade and mutational status by use of perfusion-based magnetic resonance imaging.

Authors:  Lusien van Santwijk; Valentina Kouwenberg; Frederick Meijer; Marion Smits; Dylan Henssen
Journal:  Insights Imaging       Date:  2022-06-07

2.  Perfusion, Diffusion, Or Brain Tumor Barrier Integrity: Which Represents The Glioma Features Best?

Authors:  Lin-Feng Yan; Ying-Zhi Sun; Sha-Sha Zhao; Yu-Chuan Hu; Yu Han; Gang Li; Xin Zhang; Qiang Tian; Zhi-Cheng Liu; Yang Yang; Hai-Yan Nan; Ying Yu; Qian Sun; Jin Zhang; Ping Chen; Bo Hu; Fei Li; Teng-Hui Han; Wen Wang; Guang-Bin Cui
Journal:  Cancer Manag Res       Date:  2019-11-27       Impact factor: 3.989

3.  Non-Invasive Estimation of Glioma IDH1 Mutation and VEGF Expression by Histogram Analysis of Dynamic Contrast-Enhanced MRI.

Authors:  Yue Hu; Yue Chen; Jie Wang; Jin Juan Kang; Dan Dan Shen; Zhong Zheng Jia
Journal:  Front Oncol       Date:  2020-12-08       Impact factor: 6.244

Review 4.  Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in glioma.

Authors:  Cathy W Levenson; Thomas J Morgan; Pamela D Twigg; Timothy M Logan; Victor D Schepkin
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 5.  Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.

Authors:  Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.